Monopar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Monopar Therapeutics

11/05/2023 12:59

* Monopar Therapeutics Inc  MNPR.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 22 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Monopar Therapeutics Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Monopar Therapeutics Inc shares had fallen by 28.1% this
quarter and lost 57.8% so far this year.
    * The company reported a quarterly loss of $2.43 million.
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 11:59 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.22          -0.19          Beat
 Dec. 31 2022      -0.20          -0.23          Missed
 Sep. 30 2022      -0.22          -0.19          Beat
 Jun. 30 2022      -0.21          -0.22          Missed